Browse hierarchy: [Hematology (HE)](/submissions/HE) → [Subpart B — Biological Stains](/submissions/HE/subpart-b%E2%80%94biological-stains) → [21 CFR 864.1860](/submissions/HE/subpart-b%E2%80%94biological-stains/864.1860) → SER — Immunohistochemistry Assay, Antibody, Met

# SER · Immunohistochemistry Assay, Antibody, Met

_Hematology · 21 CFR 864.1860 · Class 3_

**Canonical URL:** https://fda.innolitics.com/submissions/HE/subpart-b%E2%80%94biological-stains/SER

## Overview

- **Product Code:** SER
- **Device Name:** Immunohistochemistry Assay, Antibody, Met
- **Regulation:** [21 CFR 864.1860](/submissions/HE/subpart-b%E2%80%94biological-stains/864.1860)
- **Device Class:** 3
- **Review Panel:** [Hematology](/submissions/HE)

## Identification

Immunohistochemistry test systems (IHC's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. Their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. Similar devices intended for use with flow cytometry devices are not considered IHC's.

## Classification Rationale

(1) Class I (general controls). Except as described in paragraphs (b)(2) and (b)(3) of this section, these devices are exempt from the premarket notification requirements in part 807, subpart E of this chapter. (2) Class II (special control, guidance document: “FDA Guidance for Submission of Immunohistochemistry Applications to the FDA,” Center for Devices and Radiologic Health, 1998). (3) Class III (premarket approval). IHC's intended for any use not described in paragraphs (b)(1) or (b)(2) of this section.

## Special Controls

(2) Class II (special control, guidance document: “FDA Guidance for Submission of Immunohistochemistry Applications to the FDA,” Center for Devices and Radiologic Health, 1998). These IHC's are intended for the detection and/or measurement of certain target analytes in order to provide prognostic or predictive data that are not directly confirmed by routine histopathologic internal and external control specimens. These IHC's provide the pathologist with information that is ordinarily reported as independent diagnostic information to the ordering clinician, and the claims associated with these data are widely accepted and supported by valid scientific evidence. Examples of class II IHC's are those intended for semiquantitative measurement of an analyte, such as hormone receptors in breast cancer.

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [P240037](https://fda.innolitics.com/submissions/HE/subpart-b%E2%80%94biological-stains/SER/P240037.md) | VENTANA MET (SP44) RxDx Assay | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | May 14, 2025 | APPR |

## Top Applicants

- Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/HE/subpart-b%E2%80%94biological-stains/SER](https://fda.innolitics.com/submissions/HE/subpart-b%E2%80%94biological-stains/SER)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com